| 89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察 |
| |
| 引用本文： | 董占飞,秦永德,王新华. 89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察[J]. 中国肿瘤临床, 2012, 39(21): 1660-1662. DOI: 10.3969/j.issn.1000-8179.2012.21.024 |
| |
| 作者姓名： | 董占飞 秦永德 王新华 |
| |
| 作者单位： | ①.新疆医科大学第一附属医院核医学科（乌鲁木齐市830000） |
| |
| 摘 要： | 目的 观察89SrCl2、89Sr联合99Tc-MDP、89Sr联合唑来膦酸治疗肺癌骨转移的疗效。 方法 95例肺癌骨转移患者随机分为对照组(33例)与试验组A(30例)、试验组B(32例), 分别用89Sr治疗、89Sr联合99Tc-MDP治疗, 89Sr联合唑来膦酸治疗。主要观察三组患者治疗前后的疼痛、生活质量、血象、骨显像所示骨转移灶数目的改善情况。计数资料采用卡方检验, 计量资料采用均数t检验。 结果 对照组、试验组A、试验组B骨痛缓解有效率分别为57.58%、83.33%、81.25%。经统计分析, 试验组A、B与对照组骨痛缓解有效率、全身状况Karnofsky评分提高率(51.52%、80.00%、71.88%)、骨转移病灶治疗有效率(60.61%、83.33%、84.38%), 三组间有效率差异有统计学意义(P均 < 0.05), 而不良反应试验组无明显增加(χ2=1.885, P > 0.05)。 结论 89Sr联合99Tc-MDP、89Sr联合唑来膦酸的治疗方法较单独使用89Sr均能显著提高缓解疼痛的临床疗效。
|
| 关 键 词： | 89Sr 99Tc-MDP 唑来膦酸 肺肿瘤 治疗骨肿瘤 |
| 收稿时间： | 2012-06-21 |
Clinical Observation of Internal Radiotherapy using 89Sr99Tc-MDP and Zoledronic Acid in the Treatment and Pain Relief of Lung Cancer Patients with Bone Metastasis |
| |
| Zhanfei DONG,Yongde QING,Xinhua WANG. Clinical Observation of Internal Radiotherapy using 89Sr99Tc-MDP and Zoledronic Acid in the Treatment and Pain Relief of Lung Cancer Patients with Bone Metastasis[J]. Chinese Journal of Clinical Oncology, 2012, 39(21): 1660-1662. DOI: 10.3969/j.issn.1000-8179.2012.21.024 |
| |
| Authors: | Zhanfei DONG Yongde QING Xinhua WANG |
| |
| Affiliation: | ①.Department of Nuclear Medicine, The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830000, China②.Department of Nuclear Medicine, Cancer Hospital Affiliated from Xinjiang Medical University, Urumqi 830000, China |
| |
| Abstract: | Objective To evaluate the palliative effect on pain relief in lung cancer patients with bone metastasis treated with 89Sr and 99Tc-MDP, 89Sr and zoledronic acid, and 89Sr alone. Methods Ninety-five lung cancer patients with bone metastasis were randomly divided into experimental groups A, B, and the control. The control group (33 patients), group A (30 patients), and group B (32 patients) were treated with 89Sr only, 89Sr combined with 99Tc-MDP, and 89Sr combined with zoledronic acid, respectively. Improvements in pain, quality of life, blood routine, and the number of bone metastases were mainly observed before and after treatment.χ2 test was performed to analyze data. Results The overall palliative pain relief rates in the experimental treatment groups A and B were 81.25% and 83.33%, respectively. For the control group, the palliative pain relief rate was 57.58%. Statistically significant differences in the overall palliative pain relief rate (χ2=6.801) were observed among groups A, B, and the control with single-treatment modalities. Significant dif-ferences were also observed in the improvement of the whole-body Kamofsky performance status score (51.52%, 80.00%, and 71.88%; χ2=6.246) and focal palliative rate (60.61%, 83.33% and 84.38%; χ2=6.362). Side effects did not increase significantly (χ2=1.885, P> 0.05). Conclusion The combined treatments of 89Sr and 99Tc-MDP as well as 89Sr and zoledronic acid are more effective than the single-treatment modalities in bone pain relief associated with bone metastasis. These combinations can significantly improve the efficacy of the treatment of bone metastasis in lung cancer patients. |
| |
| Keywords: | |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
